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OBJECTIVES The goal of this study was to assess the short- and long-term efficacy of different thrombolytic
therapy regimens in patients with leg or pelvic deep venous thrombosis (DVT).
BACKGROUND It is unclear whether locoregional or systemic thrombolysis is superior in treating acute leg
DVT or even whether lysis is more effective than anticoagulation therapy in preventing
postthrombotic syndrome.
METHODS A total of 250 patients averaging 40 years of age with acute DVT were randomized into five
groups to receive full heparinization (1,000 IU/h) and compression treatment, with four
groups also administered locoregional tissue plasminogen activator (20 mg/day) or urokinase
(100,000 IU/day) or systemic streptokinase (3,000,000 IU daily) or urokinase (5,000,000 IU
daily). All groups then received anticoagulation and compression treatment for one year.
Primary efficacy criteria included the change after one year in the number of closed vein
segments and the occurrence of postthrombotic syndrome.
RESULTS Systemic thrombolytic therapy significantly reduced the number of closed vein segments after
12 months in patients with acute DVT compared with conventional treatment (p , 0.05).
Postthrombotic syndrome also occurred with less frequency in systemically treated patients
versus controls (p , 0.001). High-dose thrombolysis led to better rates of complete
recanalization after seven days (p , 0.01) than locoregional lysis. However, 12 patients
receiving thrombolysis (9 systemic, 3 local) suffered major bleeding complications; 9 patients
on systemic treatment developed pulmonary emboli.
CONCLUSIONS Systemic thrombolytic treatment for acute DVT achieved a significantly better short- and
long-term clinical outcome than conventional heparin/anticoagulation therapy but at the
expense of a serious increase in major bleeding and pulmonary emboli. Given the inherent
risks for such serious complications, systemic thrombolysis, although effective, should be used
selectively in limb-threatening thrombotic situations. (J Am Coll Cardiol 2000;36:1336–43)
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Although numerous studies have been conducted for well
over a decade to assess the efficacy and safety of thrombo-
lytic therapy for deep venous thrombosis (DVT), no con-
sensus has emerged with regard to the drug of choice, best
route of administration (locoregional vs. systemic) and
optimal dosing regimen. Various ways and means of im-
proving recanalization rates and preventing bleeding com-
plications have been suggested (1–6), but diverse protocols
and conflicting results have only served to obfuscate the
clinical picture. For example, two studies on acute leg DVT
carried out in 1992 indicated that locoregional fibrinolysis
with either recombinant tissue plasminogen activator (rt-
PA) (7) or urokinase (8) was safer and more effective than
systemic thrombolysis. However, a more recent investiga-
tion (9) appeared to negate these findings in favor of
systemic treatment. Moreover, because long-term studies
after thrombolysis treatment have not rigorously monitored
compliance with respect to follow-up compression therapy,
it is unclear whether thrombolytic treatment strategies are
more effective than exclusive anticoagulation therapy in
preventing the subsequent development of the postthrom-
botic syndrome (PTS). Consequently, the use of thrombo-
lytic therapy is far from being generally accepted, and the
benefits and risks of such treatment must be weighed with
care for each patient (10–13). Against this background, the
aim of this randomized controlled study was to determine
the rate of primary recanalization in comparable DVT
patient groups receiving low-dose locoregional (rt-PA or
urokinase) or high-dose systemic (urokinase or streptoki-
nase) thrombolytic therapy. We also sought to establish
whether such treatments prevented the long-term occur-
rence of PTS when compared with the use of anticoagula-
tion therapy and compression bandages only.
METHODS
Patients. Between January 1992 and January 1998, 250
patients (mean age 39.9 6 10.4 years) with recent, acute leg
or pelvic thromboses (mean duration of symptoms 5.6 6 2.1
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days), but without clinically relevant signs of pulmonary
embolism, were recruited at our hospitals in Chemnitz and
Dresden for this trial which consisted of a four- to seven-
day randomized acute treatment phase (thrombolytic ther-
apy) followed by a year-long phase during which patients
received standard anticoagulant and compression treatment.
The diagnosis and onset of the thrombosis were based upon
the nature and date of the initial clinical symptoms, venog-
raphy and the findings of color-coded duplex sonography
after two independent examinations. Evidence of thrombo-
sis on color-coded duplex sonography was carried out
through compression findings and by diagnosing the ab-
sence of color flow. Patients could only be included if the
estimated age of the leg or pelvic DVT in the two
sonographic examinations did not differ by more than three
days (thereby excluding the emergence of a new obstruction)
and provided that the thrombosis was less than nine days
old.
Proximal leg DVT was defined as thrombosis of the
popliteal or more proximal veins with or without concom-
itant calf vein thrombosis. The anatomical levels of the
thrombi were defined as follows: lower leg, thrombus in the
tibial vein or anterior or posterior or fibular or soleus veins;
popliteal, thrombus in the popliteal or gastrocnemius veins;
thigh, thrombus in the superficial femoral or deep femoral
veins; pelvic, thrombus in the pelvic veins. Exclusion criteria
were as follows: patients with DVT solely at one level;
existence of DVT for more than nine days; previous DVT in
the same leg or thrombosis in calf veins only; urogenital or
gastrointestinal bleeding; inflammatory bowel disease
within the last 12 months; acute pancreatitis; surgical
intervention or cerebral trauma within the last three
months; intramuscular injections within the last 10 days;
arterial hypertension or diabetes (stages III to IV retinopa-
thy); history of cerebral disease; malignant disease; renal
failure (creatinine .350 mM); hepatic failure (ASAT .
100 U/l; prothrombin time .50%), hemorrhagic diathesis;
pregnancy or lactation; delivery within the last 20 days.
Written informed consent for the study was obtained from
all subjects, and the protocol was approved by the local
ethics committee of the University of Dresden.
Therapeutic regimens. Upon eligibility for inclusion, pa-
tients were randomly assigned to one of the five following
groups.
LOCO-REGIONAL RT-PA. Twenty-mg rt-PA (Alteplase,
Thomae, Boehringer Ingelheim, Germany) was infused
directly into the affected leg via a dorsal pedal vein over a
4-h period each day for four to seven days. During this time,
standard unfractionated heparin (Liquemin, Hoffmann-La
Roche, Grenzach-Wyhlen, Germany) was continuously ad-
ministered intravenously at a rate of 1,000 IU/h, with the
dosage adjusted according to the aPTT value (2.0 to 3.0
times normal value). Patients were kept in bed, and the
affected leg was bandaged from forefoot to groin as de-
scribed by Timmermann et al. (7).
A clinical evaluation was performed daily. If clinical
improvement was noted, a second venography was per-
formed after the first four days of treatment. However, if
venography showed no improvement or only a minor
thrombolytic effect (partial thrombolysis .50%), treatment
was continued for another three days. A third and final
venography was then performed within 24 h after cessation
of treatment. After day 7, this and the other four groups
were placed on a 12-month regimen consisting of compres-
sion treatment and oral anticoagulation with phenprocou-
mon (Falithrom, Hexal, Holzkirchen, Germany) given in
individual doses so that the international normalized ratio
was greater than 2.5 but less than 4.0.
LOCOREGIONAL UROKINASE. In the same way, 100,000 IU/h
urokinase (urokinase, Hoechst, Berlin, Germany) was infused
directly and continuously for up to seven days. Infusion was
stopped if the fibrinogen value was below 1.5 g/l or if the
plasminogen values were less than 60%. Concomitant treat-
ment was carried out with unfractionated heparin and com-
pression bandages.
SYSTEMIC UROKINASE. The patients received a bolus of
5,000,000 IU urokinase (Hoechst) daily, infused over a 4-h
period for a maximum of seven days along with unfraction-
ated heparin and compression bandages.
SYSTEMIC STREPTOKINASE. After premedication with
100 mg hydrocortisone, 50 mg ranitidine and 2 mg clem-
astine, patients were given a daily intravenous infusion of
3,000,000 IU streptokinase (Awelysin, Dresden Drug Co.,
Dresden, Germany) over 6 h, in conjunction with hepa-
rinization and compression bandages for up to seven days.
HEPARIN CONTROL. During the first seven days or less, the
only treatment received, aside from compression bandages,
was heparinization.
Efficacy and safety outcome measures. The primary out-
come measures used to assess drug efficacy in the five
treatment groups included: 1) the change in the number of
closed vein segments ($50% stenosis or total occlusion)
after 12 months; and 2) the degree of PTS after 12 months
as determined by venography. Secondary efficacy assessment
criteria included the number of closed vein segments after
seven-day lysis treatment and the phlebodynamically mea-
sured rates of venous reflux, reflux time and pressure
decreases after 12 months.
In order to assess short-term thrombolytic efficacy, all
patients underwent renewed venography and color-coded
duplex sonography at the end of seven-day lysis treatment.
One dedicated radiologist, blinded to the patients’ treat-
ment regimens, evaluated the venograms, while another
Abbreviations and Acronyms
DVT 5 deep venous thrombosis
PTS 5 postthrombotic syndrome
rt-PA 5 recombinant tissue plasminogen activator
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assessed the sonographic data. Based on visual quantitative
assessment, results were classified into five categories: pro-
gression of thrombosis, no thrombus reduction, partial
thrombolysis , 50%, partial thrombolysis $50%, complete
recanalization of all affected veins. Categorization into the
latter two groups was based on detection of continuous flow
of contrast medium in the affected veins.
The accuracy and reproducibility of the phlebographic
results were also determined. For this purpose, intraobserver
variability was initially ascertained in 20 patients and by 100
measurements of all venous segments. Additionally, inter-
observer variance was established in separate experiments
involving three observers taking four repeated measure-
ments of the venous segments for each of 20 patients. For
phlebographic evaluation of venous segments, intraobserver
variance was found to be 2.5%, and interobserver variance
was also 2.5%, while phlebodynamic measurements yielded
intra- and interobserver variances of 4% and 5%, respec-
tively. Upon evaluation of the maximal rates of reflux and
reflux times by color-coded duplex sonography, both intra-
and interobserver variance were found to be 5%.
Safety assessments after seven-day thrombolysis treat-
ment included clinical observations of the number, types,
intensity and duration of adverse events (bleeding compli-
cations, embolism, etc.) as well as determination of labora-
tory parameters. Biochemical parameters assessed before
and at the end of treatment included electrolytes, creatinine
and ASAT. Measurements of hemoglobin, hematocrit,
platelets, as well as coagulation tests (aPTT, thrombin time,
PTT and fibrinogen) were performed twice daily. Anti-
thrombin III levels were determined before administration
of heparin. Adverse events were considered to be major if
they required early cessation of treatment.
After 12 months, all patients attended a follow-up exam-
ination during which they filled in a standardized question-
naire describing their subjective symptoms indicative of the
clinical grade of PTS: stage I, no symptoms; stage II, slight
symptoms corresponding to mild, perimalleolar edema for-
mation reversible overnight, perimalleolar “piston veins,”
coronal phlebectasia; stage III, moderate symptoms, i.e.,
visible, palpable edema up to the midcalf level, hyperpig-
mentation in the distal calf region, hyperdermitic changes in
the subcutis, especially in the perimalleolar region, hyper-
eczematization and induration of the subcutaneous lipid
tissue (lipodermatosclerosis); stage IV, serious symptoms,
i.e., healed or active ulceration and additional signs of
congestion as in stage III.
An evaluation of the deep venous system in the affected
extremity was then performed. In order to estimate the
degree of PTS after 12 months, the following venographic
criteria was used: 1) recanalized vessel with smooth vessel
wall, 2) clear damage to the vessel wall with partial recan-
alization but residual multiple stenoses and formation of
collateral venous vessels, 3) only slight recanalization with
clear collateralization, 4) lack of recanalization with com-
plete collateral circulation and venous occlusions remaining
unchanged. This venographic study was carried out by two
independent investigators who were blinded to the thera-
peutic regimen.
For additional validation of venous function, phlebody-
namic measurements were also performed. The values were
newly assigned. Such measurements make it possible to
describe venous reflux function (drainage function) quanti-
tatively by determining peripheral blood pressure (dorsal
pedal vein) with the patient standing upright. Thereafter,
standardized weight-bearing on the toes was performed and
the loading phlebodynamics measured. Immediately after
the normalized toe-standing exercises, the absolute maximal
drop in pressure was determined. The latter variable is one
of the best reproducible indicators of venous pump function
and can be classified into the following grades: grade I, no
PTS, i.e., unremarkable valve function with pressure drop of
60 mm Hg 6 8 mm Hg; grade II, pressure drop 50 mm Hg
6 20 mm Hg; grade III, pressure drop 20 mm Hg 6
11 mm Hg; grade IV, no pressure drop, i.e., completely
obliterated valve function reflecting serious PTS.
Before venography, all patients were examined in a
standing position using continuous wave Doppler, B-mode
sonography and color-coded duplex sonography with and
without flow rate measurements in the common femoral,
superficial femoral and popliteal veins. Discrete refluxes in
the deep veins of the lower leg were not considered. Using
color-coded duplex sonography, a change in color was
sought in the low-flow area (0.5 to 20 cm/s) by means of
three Valsalva maneuvers. Only a change lasting more than
0.5 s, in the color-coded direction of flow during application
of pressure, was defined as reflux. The measurements were
recorded at an angle below 60°. The mean value of the
maximal reflux speed (cm/s) was calculated from three
measurements. B-mode sonography in the deep veins of the
leg was based on pathological vessel wall changes, the
so-called inner reflexes. Additionally, the reflux above the
popliteal vein was measured under standardized conditions.
Rates of reflux exceeding 10 cm/s and reflux times greater
than 2 s were considered to be pathological. The reference
method used in all patients was antegrade venography with
pressure tests using the customary technique.
The Doppler examination was carried out using the
bidirectional continuous wave Doppler Vasoscop (Kranz-
bu¨hler, Solingen, Germany) with 4- and 8-MHZ probes.
Color-coded duplex sonography was performed using the
Sonos 1000 system (Hewlett Packard, Frankfurt, Germa-
ny), with 5- and 7.5-MHZ transducers. Finally, follow-up
sonography, just as for venography, was carried out by a
blinded investigator with no knowledge as to the initial
treatment procedures that had been used.
Statistical methods. Data are expressed as mean 6 stan-
dard deviation. Comparisons between the groups were carried
out using Bonferoni-adjusted chi-square and Mann-Whitney
U tests. For the analysis of the vein segments, statistical tests
were carried out on the basis of Bonferoni-Holm-adjusted
contrasts in a logistic regression model. For this purpose, the
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outcome variable was a “closed vein segment,” while the
three factors included follow-up time, treatment group and
level of affected area and with an exchangeable correlation
matrix for all outcomes within the individual patients (14).
These tests examined the hypotheses concerning the equal-
ity of the expected number of closed vein segments between
each of the treatment groups: 1) before lysis, 2) after 12
months, and 3) the expected decrease in closed vein seg-
ments after 12 months. For this analysis, the SAS procedure
GENMOD (SAS Institute; Cary, North Carolina) was
used. With a presumed dropout rate of 20%, we estimated
that a sample size of 5 3 40 patients was necessary to
achieve sufficient statistical power of at least 90% for a
relative effect equal to 60% of the standard deviations of the
variables tested.
RESULTS
Baseline characteristics. A total of 250 patients were
equally randomized to the five treatment groups. As seen in
Table 1, no significant intergroup differences emerged with
respect to demographic and baseline characteristics. The
principal causes of thrombosis were immobilization (32%),
idiopathic thrombosis (32%), antithrombin deficiency
(16%), patients with familial thrombophilia taking hor-
monal contraceptives (16%) and protein C defects (4%).
Patient disposition. In the course of the acute treatment
phase, lysis treatment had to be terminated earlier than
seven days in a total of 12 patients due to major bleeding
complications: two because of persistent nosebleeds, three
due to important skin hematomas (.8 cm diameter), one
patient with gastrointestinal bleeding, two with hematuria
and four with retroperitoneal bleeding. Three of these
patients received local thrombolytic treatment, while the
other nine underwent systemic thrombolysis. All complica-
tions could be well controlled conservatively, and no cerebral
hemorrhaging or fatal complications occurred. In contrast
with patients receiving thrombolytic treatment, no gastro-
intestinal bleeding, hematuria or retroperitoneal bleeding
occurred in the control group. After initiation of lysis on the
first day of treatment, five and four patients in the systemic
streptokinase and urokinase groups, respectively, showed
clinical signs of pulmonary embolism, accompanied by lack
of air, thoracic pain and a slight drop in blood pressure.
Lysis treatment was continued, and the symptoms did not
last longer than 30 min. No symptomatic pulmonary em-
bolism was observed among controls.
The follow-up examination at month 12 was not at-
tended by four patients in the systemic urokinase group,
four in the systemic streptokinase group and four in the
control group. These were primarily patients who suffered
from very few symptoms and did not appreciate the reasons
for compression treatment, let alone the need for the
follow-up examination. There was no mortality, hemor-
rhagic complications or evidence of pulmonary embolisms
among patients during the one-year follow-up phase.
Primary outcome measures. When changes in the number
of closed vein segments ($50% stenosis or total occlusion)
were assessed for all patients (n 5 238) attending the
follow-up examination at 12 months, the number of re-
maining closed segments was significantly lower (p , 0.05)
in patients who had undergone systemic thrombolysis com-
pared with those on conventional treatment (Table 2). No
significant differences in outcome emerged between controls
and the patients treated locoregionally.
Upon analyzing the results in terms of the number of
anatomical levels affected (Table 2), there were no inter-
group differences in closed vein segments at 12 months for
patients affected at two levels. When three levels (lower leg,
popliteal and femoral veins) were involved, patients receiv-
ing either local or systemic lysis treatment showed signifi-
cant improvement (all p , 0.05) versus controls. However,
when evaluating those patients affected at four levels (pre-
vious set plus pelvic vein), only the systemically treated
patients demonstrated significant differences compared with
controls (p , 0.05).
With respect to the second primary end point, Table 3
summarizes the degree of PTS after 12 months as defined
by venography. There was a significantly greater number of
patients with a more favorable degree of PTS among those
treated with systemic thrombolysis versus controls (p ,
0.001). A total of 76 out of 92 patients (83%) in the former
group could be classified as having first- or second-degree
PTS versus 26/46 patients (57%) treated conventionally and
57/100 (57%) patients in the locoregional group.
Table 1. Patient Characteristics at Entry According to Treatment Group
Local Systemic
Controlrt-PA Urokinase Urokinase Streptokinase
Number 50 50 50 50 50
No. men/women 20/30 23/27 20/30 20/30 25/25
Mean age (range) 40 (22–64) 39 (25–58) 41 (23–60) 37 (22–60) 41 (21–63)
Mean age thrombosis* 5.5 6 1.6 5.6 6 2.0 5.4 6 1.9 5.7 6 2.0 5.3 6 1.9
Total no. vessel sections† 455 454 452 458 457
* Days 6 standard deviation; †vessel sections considered included: pelvic vein, femoral vein, popliteal vein, anterior tibial vein,
posterior tibial vein, fibular vein.
1339JACC Vol. 36, No. 4, 2000 Schweizer et al.
October 2000:1336–43 Thrombolytic Treatment of Deep Venous Thrombosis
Secondary outcome measures. When comparing func-
tional parameters at 12 months among patients with any
degree of PTS (Table 4), the drop in peripheral blood
pressure and the decrease in the maximal rates of reflux and
reflux times were significantly more pronounced in system-
ically treated patients (p , 0.001) versus controls.
Finally, short-term thrombolytic findings are presented in
Table 5. No reduction or worsening of thrombotic findings
occurred in 80% of controls, 31% of patients on local
thrombolysis and in 20% of patients infused systemically. By
contrast, thrombus reduction $50% or complete recanali-
zation was observed in 6%, 36% and 54% of controls,
patients on local treatment and systemic lysis, respectively.
The results of the systemic grouping with respect to the
frequency of completely reopened vessel sections were sta-
tistically significant when compared with the groups on
local lytic treatment (p , 0.01). No intergroup differences
emerged in terms of any of the hematological, biochemical
or coagulation parameters assessed before or after lysis
treatment.
DISCUSSION
Thrombolysis for acute DVT: Conflicting evidence, trial
design issues. At present, recourse to the use of thrombo-
lytic therapy in patients with acute leg DVT is not wide-
spread among physicians. For one thing, the potential
immediate benefit of preventing pulmonary embolism with
thrombolysis must actually be balanced against the potential
immediate harm of iatrogenically causing pulmonary embo-
lization or major bleeding by thrombolysis of DVT. An-
other cautionary factor has been conflicting evidence as to
whether DVT thrombolysis can prevent PTS. One influ-
ential study by Kakkar and Lawrence (15) reported no
difference between systemic streptokinase and heparin/
coumadin alone in preventing chronic venous insufficiency
Table 2. Changes in Closed or Partially Closed ($50%) Venous Segments After 12 Months
Local Treatment Systemic Treatment
Group 5
Control
Group 1
rt-PA
Group 2
Urokinase
Group 3
Urokinase
Group 4
Streptokinase
Patients affected on:
2 Levels
No. patients 23 23 19 18 19
No. segments evaluated 209 209 171 162 176
Closed* segments at:
Baseline† 155 (74%) 159 (76%) 128 (72%) 119 (75%) 131 (74%)
12 months† 66 (29%) 70 (32%) 60 (29%) 52 (36%) 66 (38%)
Percent decrease† 41% 43% 40% 41% 36%
3 Levels
No. patients 14 15 15 15 16
No. segments evaluated 127 136 136 138 145
Closed* segments at:
Baseline† 113 (89%) 119 (88%) 117 (86%) 120 (87%) 128 (88%)
12 months‡ 50 (39%) 52 (38%) 30 (22%) 38 (28%) 93 (64%)
Percent decrease‡ 50% 50% 64% 59% 24%
4 Levels
No. patients 13 12 12 13 11
No. segments evaluated 119 109 112 122 100
Closed* segments at:
Baseline† 113 (95%) 106 (97%) 107 (95%) 117 (96%) 97 (97%)
12 months§ 48 (42%) 40 (38%) 21 (20%) 23 (20%) 42 (42%)
Percent decrease§ 53% 59% 75% 76% 54%
All Patients in Follow-up
No. patients 50 50 46 46 46
No. segments evaluated 455 454 419 422 421
Closed* segments at:
Baseline† 381 (84%) 384 (85%) 352 (84%) 356 (84%) 356 (85%)
12 months\ 166 (36%) 162 (36%) 111 (26%) 113 (27%) 201 (48%)
Percent decrease\ 48% 49% 58% 57% 37%
Major bleeding 2 1 4 5 0
Noncompliance 0 0 4 4 4
*Vessel sections completely or partially ($50%) closed; †no significant differences between groups; ‡significant contrasts: local
treatment groups versus controls and systemic groups versus controls, both p , 0.05 by GENMOD SAS procedure, adjusted
over three tests between the local, systemic and control groups; §significant contrasts: local versus systemic groups and systemic
groups versus controls, both p , 0.05 by GENMOD SAS procedure, adjusted over three tests between the treatment groups;
\significant contrasts: systemic versus control groups, p , 0.05 by GENMOD SAS procedure, adjusted over three tests between
the local, systemic and control groups.
no. 5 number; rt-PA 5 recombinant tissue plasminogen activator.
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in the long term, but several other investigations carried out
about 15 to 20 years ago appear to indicate that lytic therapy
reduces late postthrombotic sequelae to a markedly greater
extent than anticoagulant therapy alone (16–21). Unfortu-
nately, the variegated design of these trials has limited their
comparability, thereby failing to resolve such key issues as
what types of DVT patients would benefit most from
thrombolysis and which thrombolytic agent(s) and dosing
regimen(s) would be the most effective.
A particularly problematic factor in previous investiga-
tions is the question of longer-term follow-up. In fact,
studies of later sequelae after lysis treatment should be run
ideally for five to 10 years. But this is an inordinately long
time to monitor patient compliance, especially with regard
to controlled compression therapy. It is well known that
patients with vascular complaints are likely to avoid this
form of treatment during summer months, favoring the
development of PTS. In order to achieve a practical and
uniform regimen for follow-up, the end point of our study
was set at one year. In addition to receiving oral anticoag-
ulation, all patients underwent compression treatment using
custom-measured class 2 compression stockings fitted by
Table 3. Degree of Postthrombotic Syndrome as Defined by Venographic Criteria* After
12 Months
Findings
Local Treatment Systemic Treatment
Group 5
Control
(n 5 50)
Group 1
rt-PA
(n 5 50)
Group 2
Urokinase
(n 5 50)
Group 3
Urokinase
(n 5 50)
Group 4
Streptokinase
(n 5 50)
Degree of postthrombotic syndrome:†
I 11 13 14 23 5
II 18 15 19 20 21
III 20 21 12 3 20
IV 1 1 1 0 0
Noncompliance 0 0 4 4 4
Major bleeding complications 2 1 4 5 0
*Degree of postthrombotic syndrome defined as follows: I 5 recanalized vessel with smooth vessel wall, II 5 clear damage to
the vessel wall with partial recanalization but residual multiple stenoses and formation of collateral venous vessels, III 5 only
slight recanalization with clear collateralization, IV 5 lack of recanalization with complete collateral circulation and venous
occlusions remaining unchanged; †significant for systemic groups versus controls (p , 0.001, Bonferroni-adjusted chi-square
test).
rt-PA 5 recombinant tissue plasminogen activator.
Table 4. Follow-up Results After 12 Months Comparing Patients With and Without
Postthrombotic Syndrome
Findings
Local Treatment Systemic Treatment
Group 5
Control
(n 5 50)
Group 1
rt-PA
(n 5 50)
Group 2
Urokinase
(n 5 50)
Group 3
Urokinase
(n 5 50)
Group 4
Streptokinase
(n 5 50)
No postthrombotic syndrome* 11 13 14 23 5
Pressure decrease† (mm Hg 6 SD) 62 6 11 60 6 8 63 6 12 61 6 8 63 6 10
Reflux in popliteal vein
Maximum rate of:
Reflux† (cm/s 6 SD) 5.0 6 1.3 5.0 6 1.5 4.1 6 1.6 5.9 6 1.6 6.0 6 1.0
Reflux time† (s 6 SD) 0.5 6 0.1 0.6 6 0.1 0.6 6 0.2 0.6 6 0.2 0.5 6 0.1
Postthrombotic syndromes 39 37 32 23 41
Pressure decrease‡ (mm Hg 6 SD) 22 6 12 25 6 12 40 6 15 49 6 10 18 6 12
Reflux in popliteal vein
Maximum rate of:
Reflux‡ (cm/s 6 SD) 42.1 6 19.2 41.8 6 16.9 25.3 6 15.5 23.2 6 12.6 45.7 6 14.8
Reflux time‡ (s 6 SD) 4.3 6 1.2 4.1 6 1.4 2.7 6 1.0 2.7 6 1.0 4.3 6 1.1
INR value
After 6 months§ 6 SD 2.9 6 0.1 3.0 6 0.2 3.0 6 0.2 3.0 6 0.3 3.0 6 0.3
After 12 months§ 6 SD 2.9 6 0.3 2.8 6 0.2 2.9 6 0.3 2.9 6 0.3 2.9 6 0.2
Noncompliance 0 0 4 4 4
Major bleeding complications 2 1 4 5 0
*Significant for systemic groups versus controls (p , 0.001, Bonferroni-adjusted chi-square test); †not significant (GENMOD
SAS procedure); ‡significant for systemic versus local or control groups (p , 0.01, GENMOD SAS procedure); §not significant.
Pressure decrease refers to drop in peripheral blood pressure measured phlebodynamically.
INR 5 international normalized ratio; rt-PA 5 recombinant tissue plasminogen activator; SD 5 standard deviation.
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the orthopedic technician. These stockings were refitted
every three months, at which time patients were required to
hand in their compression stockings for visual inspection. In
this respect, compliance was surprisingly good in all patients
who attended the final checkup after 12 months despite the
subjectively stressful compression treatment.
Another issue in the design of trials to assess postthrom-
botic venous changes is the difficulty in initially assigning a
clinical age to the thrombosis based on the duration of
symptoms. It must be assumed that some patients are
inadvertently included with asymptomatic thromboses but
which only become apparent when clinical symptoms arise.
Indeed, PTS grades 3 and 4 were found in all our groups
after one year although it is well known that such conditions
only develop after five to 10 years. This demonstrates the
difficulties in carrying out studies intended to include only
those patients with primary manifestations of venous
thrombosis.
It is also true that a standardized questionnaire such as
that filled in by patients to assess the presence and degree
of PTS is subject to bias due to the absence of blinding. To
avoid such bias, a venographic study was carried out by
independent investigators who were blinded to the thera-
peutic regimen. Additionally, a phlebodynamic comparison
of no symptoms versus any symptoms was carried out
(Table 4).
Principal efficacy and safety results. Upon taking into
account all 238 patients who could be followed up for 12
months, a significant difference emerged for the number of
closed vessel segments after one year between patients who
had received systemic thrombolytic therapy and those ad-
ministered heparin plus oral anticoagulants. This difference
did not extend to those patients who had undergone
locoregional treatment. Venographic evidence of PTS at
month 12 was also clearly ameliorated with systemic treat-
ment versus controls. However, while this study was positive
for both end points, it should be emphasized that these
improvements were obtained at the expense of important
bleedings in 12 lysis patients and symptomatic pulmonary
emboli in 9 patients on thrombolysis, whereas no compli-
cations arose in patients on conventional therapy. As this
important rate of serious adverse effects occurred in a
40-year-old target population, the extrapolation of using
such a therapeutic strategy to a more elderly population
would conceivably result in a more unfavorable ratio of risk
to reward.
Reconciling recanalized veins and PTS. As pointed out
by Evers and Wupperman (22), it is not infrequent to
encounter patients who claim to suffer from considerable
PTS symptoms but in whom no objective skin changes can
be seen. However, by determining the rate of flow and the
reflux times, they claimed that it was possible to objectively
estimate the extent to which PTS has developed (22). In
accordance with their findings, we observed that those
patients with venographically unremarkable deep veins who
complained about considerable postthrombotic symptoms
after 12 months had significantly higher rates of reflux and
longer reflux times. We also found that patients without any
clinical symptoms of PTS demonstrated unremarkable re-
sults on venography and had no pathological reflux times or
reflux measured over the popliteal vein in color-coded
duplex sonography (Table 4). Not only did our phlebody-
namic measurements and those by color-coded duplex
sonography correlate well for reflux (r 5 0.87, p 5 0.001)
and for reflux time (r 5 0.93, p 5 0.001), but we also found
a positive correlation between phlebodynamic measure-
ments and clinical symptoms of PTS (r 5 0.96, p 5 0.001).
It would, thus, appear that for the longer-term development
of postthrombotic conditions, not only is the patency of the
deep veins an important factor but the quality of venous
valve function is as well. Postthrombotic syndrome cannot,
therefore, be ruled out, even if the veins have regained full
Table 5. Efficacy and Safety Results After 7 Days According to Venographic Findings
Findings
Local Systemic
Control
(n 5 50)
rt-PA
(n 5 50)
Urokinase
(n 5 50)
Urokinase
(n 5 50)
Streptokinase
(n 5 50)
Efficacy
Progression of thrombosis 4* 3 2 2 2
No thrombolysis 13 11 8 8 38
Thrombolysis ,50% 16 17 13 13 7
Thrombolysis $50% 7 9 10 7 2
Complete thrombolysis 10 10 17 20 1
Total no. vessel sections† 455 454 452 458 457
No. closed vessel sections before lysis‡ 381 384 350 353 356
No. closed vessel sections after 7 days§ 105 103 67 68 295
Safety
Pulmonary embolism 0 0 4 5 0
Major bleeding complications\ 2 1 4 5 0
*No. patients; †vessel sections considered: pelvic vein, femoral vein, popliteal vein, anterior tibial vein, posterior tibial vein, fibular
vein; ‡vessel sections partially closed $50% or completely closed, each closed section received 1 point; §systemic groups versus
local groups, p , 0.01 by GENMOD SAS procedure; \complications requiring termination of lysis treatment earlier than 7 days.
No. 5 number; rt-PA 5 recombinant tissue plasminogen activator.
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patency after lysis treatment since venous valves may have
been destroyed. Additionally, the use of reflux measure-
ments can help provide a basis for judging the need for
compression therapy.
Conservative treatment options with heparin and com-
pression bandages also gave good recanalization rates after
one year. But it should be noted that relatively poor
functional results (low reflux pathology) emerged in heparin
control patients, giving rise to more symptoms of PTS,
possibly on account of the relatively slow recanalization
process that developed over the course of one year. We
observed also that patients affected by thromboses at only
two levels seemed to benefit less from lysis treatment than
those with thrombus formation at three levels or more. The
patients in this former group often had thrombi in the pelvic
region, which are know to be less susceptible to successful
lysis due to early collateral formation. Lysis medication may,
thereby, fail to reach thromboses pelvic veins due to circu-
latory bypasses (21). Finally, this may also explain the
differing results reported by Kakkar and Lawrence (15)
versus others (16–21) with respect to the efficacy of throm-
bolysis, namely that the selected study populations would
have differed in the percentages of patients with thromboses
at two, three or four anatomical levels, thereby making them
more or less susceptible to benefitting from lysis treatment.
In conclusion, in this relatively younger population of
patients with acute leg or pelvic DVT, systemic thrombo-
lytic therapy reduced the number of closed vein segments
after 12 months and was better able to prevent postphlebitic
disability than conventional anticoagulation treatment.
However, thrombolysis was also associated with major
bleeding in 6% of cases and thromboembolism in nine
patients (4.5%), compared with no occurrences in those
receiving conventional regimens. These findings indicate
that systemic thrombolysis is effective in improving the
longer-term outcome of DVT but should be used selectively
in limb-threatening thrombotic situations, given the inher-
ent risks for serious complications. An equally important
observation that emerged is that PTS cannot be excluded
even if deep leg veins have regained their full patency after
lysis treatment because venous valves may have been patho-
logically damaged. Reflux measurements can be useful in
determining the quality of venous valve function and in
assessing the need for compression therapy.
Reprint requests and correspondence: Dr. Johannes Schweizer,
Klinik Chemnitz gGmbH, Krankenhaus Ku¨chenwald, Klinik fu¨r
Innere Medizin I, Bu¨rgerstrabe 2, D-09113 Chemnitz, Germany.
E-mail: arras@rcs.urz.tu-dresden.de.
REFERENCES
1. Collen D, Lijnen HR. Tissue-type plasminogen activator. Mechanism
of action and thrombolytic properties. Haemostasis 1986;16:25–32.
2. Agnelli G, Hirsh J. Optimal dosage regimens of tissue-type plasmin-
ogen activator. Sem Thromb Haemost 1987;13:160–2.
3. Levine MN, Weitz J, Turpie AGG, Anrew M, Cruickshank M, Hirsh
J. A new short infusion dosage regimen of recombinant tissue
plasminogen activator in patients with venous thromboembolic dis-
ease. Chest 1990;97:168S–71S.
4. Heimig TH, Martin M. Lyseblock-Technik: eine neue lokale Behan-
dlungsform von Unterschenkelvenen— und Arterienverschlu¨ssen.
Vasa 1992;21:289–93.
5. Mumme A, Ernst R, Kemen M, Walterbusch G, Zumtobel V.
Regionale hypertherme Fibrinolytika-Perfusion bei postoperativer
tiefer Venenthrombose. Dtsch Med Wschr 1992;117:1637–42.
6. Mumme A, Kemen M, Homann HH, Zumtobel V. Temperaturab-
ha¨ngigkeit der Fibrinolyse mit Streptokinase. Dtsch Med Wschr
1993;118:1594–6.
7. Timmermann J, Rudofsky G, Hagg N, Ranft J, Ruch U. Lokale
fibrinolytische Therapie (PLL) der tiefen Beinvenenthrombose mit
rt-PA. Phlebol 1992;21:205–9.
8. Cossio JAJ, Ortin PM, Riera L, Raparaz L. Erprobung einer neuen
Methode in der lokoregionalen Behandlung mit Urokinase bei tiefer
Venenthrombose (TVT). Phlebol 1992;21:119–22.
9. Schwieder G, Grimm W, Siemens HJ, et al. Intermittent regional
therapy with rt-PA is not superior to systemic thrombolysis in deep
vein thrombosis (DVT): a German multicenter trial. Thromb Hae-
most 1995;74:1240–3.
10. Marder VJ, Sherry S. Thrombolytic therapy: current status (first of two
parts). New Engl J Med 1988;318:1512–20.
11. Marder VJ, Sherry S. Thrombolytic therapy: current status (second of
two parts). New Engl J Med 1988;318:1585–95.
12. Brown WD, Goldhaber SZ. How to select patients with deep vein
thrombosis for tPA therapy. Chest 1989;95:176S–8S.
13. Goldhaber SZ. Thrombolysis in venous thromboembolism. An inter-
national perspective. Chest 1990;97:176S–81S.
14. Diggle PJ, Ljang KY, Zeger SL. Analysis of Longitudinal Data.
Oxford: Clarendon Press, 1994.
15. Kakkar VV, Lawrence D. Hemodynamic and clinical assessment after
therapy for acute deep venous thrombosis: a prospective study. Am J
Surg 1985;150:54–63.
16. Common HH, Seaman AJ, Rosch J, Porter JM, Dotter CT. Deep vein
thrombosis treated with streptokinase or heparin: follow-up of a
randomized study. Angiology 1976;27:645–54.
17. lliot MS, Immelman EJ, Jeffrey P, et al. A comparative randomized
trial of heparin versus streptokinase in the treatment of acute proximal
venous thrombosis: an interim report of a prospective trial. Br J Surg
1979;66:838–43.
18. Johansson L, Nylander G, Hedner U, Nilsson IM. Comparison of
streptokinase with heparin: late results in the treatment of deep venous
thrombosis. Acta Med Scand 1979;206:93–8.
19. Arneson H, Hoiseth A, Ly B. Streptokinase or heparin in the
treatment of deep vein thrombosis: follow-up results of a prospective
study. Acta Med Scand 1982;211:65–8.
20. Widmer LK, Zemp E, Widmer MT, et al. Late results in deep vein
thrombosis of the lower extremity. VASA 1985;14:264–8.
21. Comerota AJ, Aldridge SC. Thrombolytic therapy for deep venous
thrombosis: a clinical review. Can J Surg 1993;36:359–64.
22. Evers EJ, Wuppermann T. Ultraschalldiagnostik beim postthrombot-
ischen Syndrom. Ultraschall in Med 1995;16:259–63.
1343JACC Vol. 36, No. 4, 2000 Schweizer et al.
October 2000:1336–43 Thrombolytic Treatment of Deep Venous Thrombosis
